Focused On-demand Library for Transmembrane 4 L6 family member 20

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q53R12

UPID:

T4S20_HUMAN

Alternative names:

Alternative UPACC:

Q53R12; B2RP42; Q5U609; Q6UWS1; Q9H5X9

Background:

Transmembrane 4 L6 family member 20 (TM4SF20) is a polytopic transmembrane protein known for its role in inhibiting the regulated intramembrane proteolysis (RIP) of CREB3L1, thus preventing collagen synthesis activation. This process is influenced by ceramide, which can alter TM4SF20's membrane topology and stimulate CREB3L1's RIP activation. The unique 'regulated alternative translocation' (RAT) mechanism is pivotal in TM4SF20's function, showcasing its complex role in cellular processes.

Therapeutic significance:

TM4SF20's involvement in Specific language impairment 5, a disorder marked by delayed speech acquisition and potential cerebral abnormalities, underscores its clinical relevance. Understanding TM4SF20's function could pave the way for innovative therapeutic strategies targeting speech and developmental disorders, offering hope for affected individuals.